Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-08-09
2011-08-09
Lewis, Patrick (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S045000, C514S046000, C514S047000, C514S048000, C514S049000, C514S050000, C514S051000, C514S052000
Reexamination Certificate
active
07994143
ABSTRACT:
The present invention relates to phosphonate, nucleoside phosphonate or nucleoside phosphate compounds, compositions containing them, processes for obtaining them, and their use in treating a variety of medical disorders, in particular viral infections, cancers and the like.
REFERENCES:
patent: 4684631 (1987-08-01), Hori et al.
patent: 4797479 (1989-01-01), Shuto et al.
patent: 5512671 (1996-04-01), Piantodosi et al.
patent: 5614548 (1997-03-01), Piantadosi et al.
patent: 5633235 (1997-05-01), Townsend et al.
patent: 5770584 (1998-06-01), Kucera et al.
patent: 5827833 (1998-10-01), Townsend et al.
patent: 5962437 (1999-10-01), Kucera et al.
patent: 6030960 (2000-02-01), Morris-Natschke et al.
patent: 6413944 (2002-07-01), Townsend et al.
patent: 6670341 (2003-12-01), Kucera et al.
patent: 7026469 (2006-04-01), Kucera et al.
patent: 7129227 (2006-10-01), Kucera et al.
patent: 7135584 (2006-11-01), Kucera et al.
patent: 7141557 (2006-11-01), Kucera et al.
patent: 7294619 (2007-11-01), Kucera et al.
patent: 7294620 (2007-11-01), Kucera et al.
patent: 7294621 (2007-11-01), Kucera et al.
patent: 2002/0082242 (2002-06-01), Kucera et al.
patent: 2004/0161398 (2004-08-01), Kucera et al.
patent: 2004/0259845 (2004-12-01), Kucera et al.
patent: 2005/0080050 (2005-04-01), Kucera et al.
patent: 2005/0187191 (2005-08-01), Kucera et al.
patent: 2005/0187192 (2005-08-01), Kucera et al.
patent: 2006/0264397 (2006-11-01), Kucera et al.
patent: 2007/0099870 (2007-05-01), Kucera et al.
patent: 2007/0105811 (2007-05-01), Kucera et al.
patent: 2007/0105812 (2007-05-01), Kucera et al.
patent: 0533825 (1996-04-01), None
patent: 781138 (1997-07-01), None
patent: 1228080 (2002-08-01), None
patent: 0702556 (2002-10-01), None
patent: 01389970 (2004-02-01), None
patent: 01852121 (2007-11-01), None
patent: 02166740 (1986-05-01), None
patent: 61091195 (1986-05-01), None
patent: 61091196 (1986-05-01), None
patent: 61152694 (1986-07-01), None
patent: 61171498 (1986-08-01), None
patent: 61238797 (1986-10-01), None
patent: 62169797 (1987-07-01), None
patent: 62298597 (1987-12-01), None
patent: 05201870 (1993-08-01), None
patent: 07056033 (2007-03-01), None
patent: WO 89/07762 (1989-08-01), None
patent: WO 90/04918 (1990-05-01), None
patent: WO 91/19726 (1991-12-01), None
patent: WO 96/06620 (1994-08-01), None
patent: WO 94/28908 (1994-12-01), None
patent: WO 01/34614 (2001-05-01), None
patent: WO 02/087465 (2002-11-01), None
patent: WO 2005/087788 (2005-09-01), None
patent: WO 2005/099719 (2005-10-01), None
Hostetler et al., Synthesis and antiretroviral activity of phospholipid analogs of azidothymidine and other antiviral nucleosides.J. Biol. Chem., 265(11):6112-6117, Apr. 1990.
Hostetler et al., Enhanced inhibition of HIV replication by dideoxythymidine diphosphate diglyceride in HT4-6C cells in vitro.Clin. Res., 38(1): 115A, 1990. (Abstract).
Hostetler et al., Phospholipid derivatives of dideoxythymidine (ddT) exhibit greatly increased potency against replication of HIV in CD4-HeLa cells.J. Cell Biochem., Suppl. 14D, p. 152, 1990, (Abstract, L 423).
Kumar et al., Effect of stereoisomers of lipid analogs of zidovudine (AZT) on HIV-infected HT4-6C cells.FASEB J., 4:(7), A2259, 1990. (Abstract, 3270).
Hostetler et al., Phosphatidylazidothymidine. Mechanism of antiretroviral action in CEM cells.J. Biol. Chem., 266(18):11714-11717, Jun. 1991.
van Wijk et al., Lipid conjugates of antiretroviral agents: release of antiretroviral nucleoside monophosphate by a nucleoside diphosphate diglyceride hydrolase activity from rat liver mitochondria.Biochim. Biophys. Acta, 1084:307-310, 1991.
van Wijk et al., Cytidine diphosphate diglyceride analogs of antiretroviral dideoxynucleosides: evidence for release of dideoxynucleoside-monophosphates by phospholipid biosynthetic enzymes in rat liver subcellular fractions.Biochim. Biophys. Acta, 1086:99-105, 1991.
van Wijk et al., Lipid conjugates of antiretroviral agents: release of antiretroviral nucleoside monophosphates by a nucleoside diphosphate diglyceride hydrolase activity from rat liver mitochondria.Biochim Biophys Acta, 1084:307-310, 1991.
van Wijk et al., Antiviral nucleoside diphosphate diglycerides: Improved synthesis and facilitated purification.J. Lipid Res., 33:1211-1217, 1992.
Kumar et al., Equal inhibition of HIV replication by stereoisomers of phosphatidyl-AZT: Lack of stereospecificity of lysosomal phospholipase A1.J. Biol. Chem., 267(28):20288-20292, Oct. 1992.
Hostetler et al., Greatly enhanced inhibition of HIV-1 replication in CEM and HT4-6C cells by 3′-deoxythymidine diphosphate dimyristoylglycerol, a lipid prodrug of 3′-deoxythymidine.Antimicrob. Agents Chemotherapy, 36(9):2025-2029, Sep. 1992.
Hostetler et al., Acyclovir diphosphate dimyristoylglycerol: A phospholipid prodrug with activity against acyclovir-resistant herpes simplex virus,Proc. Nat. Acad. Sci. USA, 90:11835-11839, Dec. 1993.
van Wijk et al., Synthesis, characterization and some properties of cytidine diphosphate diglyceride analogs with antiretroviral activity.Biochim. Biophys. Acta, 1165:45-52, 1992.
Xie et al., Synthesis and antiviral activity of dipalmitoylphosphatidyldideoxyguanosine in hepatitis B virus infected cells, in vitro,FASEB J., 7:1448, 1993. (Abstract).
van Wijk et al., Synthesis and antiviral activity of 3′-azido-3′-deoxythymidine triphosphate distearoyl glycerol. A novel phospholipid conjugate of the anti-HIV agent AZT.Chemistry and Physics of Lipids, 70:213-222, 1994.
Hostetler et al., Antiviral Activity of phosphatidyl-dideoxycytidine in hepatitis-B infected cells and enhanced hepatic uptake in mice, Antiviral Res., 24:59-67, 1994.
Hostetler et al., Phosphatidyl-dideoxycytidine and phosphatidyl-ddc: Assessment of uptake in mouse lymphoid tissues, antiviral activity in HIV-infected cells and in Rauscher leukemia virus infected mice, Antimicrobial Agents Chemotherapy., 38(12):2792-2797, Dec. 1994.
Shakiba et al., Antiviral effect in human cytomegalovirus-infected cells, pharmacokinetics and intravitreal toxicology in rabbits of acyclovir diphosphate dimyristoylglycerol, Antimicrobial Agents Chemotherapy., 39(6):1383-1385, Jun. 1995.
Xie et al., Phosphatidyl-2′,3′-dideoxy-3′-thiacytidine: synthesis and antiviral activity in hepatitis B and HIV-1 infected cells, Antiviral Res., 28:113-120, 1995.
Korba et al., Liver-Targeted Antiviral Nucleosides: enhanced antiviral activity phosphatidyl-dideoxyguanosine Versus dideoxyguanosine in woodchuck hepatitis virus infection in vivo, Hepatology, 23(5):958-963, 1996.
Taskintuna et al., Evaluation of a novel lipid prodrug for intraocular drug delivery: effect of acyclovir diphosphate dimyristoylglycerol in a rabbit model with herpes simplex virus-1 retinitis, Retina, 17(1):57-64, 1997.
Hostetler et al., Antiviral activity of alkylglycerol foscarnet analogs in HIV-1 infected HT4-6C cells: structure-activity studies, 9th International Conf. on Antiviral Research, Fukushima, Japan, Antiviral Research, 30:A11, 1996. (Abstract).
Kini et al., Alkoxy Propane Prodrugs of Foscarnet: Effect of Alkyl Chain Length on In Vitro Antiviral Activity in Cells Infected with HIV-1, HSV-1 and HCMV, Antiviral Research, 36:43-53, 1997.
Rosowsky et al., Synthesis and in vitro antiviral activity of long chain 5′-(o-alkoxycarbonylphosphinytl)-3′-azido-3′-deoxythymidines against wild type and AZT- and foscarnet-resistant strains of human immunodeficiency type-1 virus (HIV-1), Proc. 10th Internat. Conf. Antiviral Research, Atlanta, Apr. 1997; Antiviral Res., 34(2): 10, 1997. (Abstract).
Beadle et al., Alkylthioglycerol prodrugs of foscarnet: oral bioavailability and structure-activity studies in human cytomegalovirus,herpes simplex virus type-1 and human immunodeficiency virus type-1 infected cells, Antiviral Chem. Chemotherapy., 9:33-40, 1998.
Cheng et al., Intravitreal toxicology of the 1-O-Octadecyl-sn-glycerol-3-phosphonoformate (ODG-PFA) and its carboxymethyl ester in liposome formulation. Investigative Ophthalmology and Visual Sciences, 39(4):S276, 1998. (Abstract, 1261-B142).
Cheng et al.
Almond Merrick R.
Beadle James R.
Francom Paula
Hostetler Karl Y.
Painter George R.
Chimerix, Inc.
Lewis Patrick
Swanson & Bratschun L.L.C.
The Regents of the University of California
LandOfFree
Metabolically stable alkoxyalkyl esters of antiviral or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Metabolically stable alkoxyalkyl esters of antiviral or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metabolically stable alkoxyalkyl esters of antiviral or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2689838